Akhtar-Zaidi B, Cowper-Sal-lari R, Corradin O, Saiakhova A, Bartels CF, Balasubramanian D, Myeroff L, Lutterbaugh J, Jarrar A, Kalady MF et al (2012) Epigenomic enhancer profiling defines a signature of colon cancer. Science 336:736–739

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bacabac M, Xu W (2023) Oncogenic super-enhancers in cancer: mechanisms and therapeutic targets. Cancer Metastasis Rev 42:471–480

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bahia RK, Lopez C, Nardocci G, Davie JR (2025) Differential H3K4me3 domains in normal and colorectal cancer cells reveal novel epigenetic targets. Int J Mol Sci 26(6):2546

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bannister AJ, Kouzarides T (2011) Regulation of chromatin by histone modifications. Cell Res 21:381–395

Article  CAS  PubMed  PubMed Central  Google Scholar 

Barski A, Cuddapah S, Cui K, Roh TY, Schones DE, Wang Z, Wei G, Chepelev I, Zhao K (2007) High-resolution profiling of histone methylations in the human genome. Cell 129:823–837

Article  CAS  PubMed  Google Scholar 

Barsoum M, Stenzel AT, Bochynska A, Kuo CC, Tsompanidis A, Sayadi-Boroujeni R, Bussmann P, Luscher-Firzlaff J, Costa IG, Luscher B (2022) Loss of the Ash2l subunit of histone H3K4 methyltransferase complexes reduces chromatin accessibility at promoters. Sci Rep 12:21506

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bates SE (2020) Epigenetic therapies for cancer. N Engl J Med 383:650–663

Article  CAS  PubMed  Google Scholar 

Baudre L, Jouault G, Prompsy P, Saichi M, Gastineau S, Huret C, Sourd L, Dahmani A, Montaudon E, Dingli F et al (2025) Characterization of drug-tolerant persister cells in triple-negative breast cancer identifies a shared persistence program across treatments and patients. Cancer Res 86(3):1–16

Google Scholar 

Belhocine M, Simonin M, Abad Flores JD, Cieslak A, Manosalva I, Pradel L, Smith C, Mathieu EL, Charbonnier G, Martens JHA et al (2022) Dynamics of broad H3K4me3 domains uncover an epigenetic switch between cell identity and cancer-related genes. Genome Res 32:1328–1342

Article  CAS  PubMed  Google Scholar 

Bentsen M, Goymann P, Schultheis H, Klee K, Petrova A, Wiegandt R, Fust A, Preussner J, Kuenne C, Braun T et al (2020) ATAC-seq footprinting unravels kinetics of transcription factor binding during zygotic genome activation. Nat Commun 11:4267

Article  CAS  PubMed  PubMed Central  Google Scholar 

Beyes S, Bediaga NG, Zippo A (2021) An epigenetic perspective on intra-tumour heterogeneity: novel insights and new challenges from multiple fields. Cancers (Basel) 13(19):4969

Article  CAS  PubMed  PubMed Central  Google Scholar 

Boyson SP, Gao C, Quinn K, Boyd J, Paculova H, Frietze S, Glass KC (2021) Functional roles of bromodomain proteins in cancer. Cancers (Basel) 13(14):3606

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bradner JE, Hnisz D, Young RA (2017) Transcriptional Addiction in Cancer. Cell 168:629–643

Article  CAS  PubMed  PubMed Central  Google Scholar 

Buenrostro JD, Wu B, Litzenburger UM, Ruff D, Gonzales ML, Snyder MP, Chang HY, Greenleaf WJ (2015) Single-cell chromatin accessibility reveals principles of regulatory variation. Nature 523:486–490

Article  CAS  PubMed  PubMed Central  Google Scholar 

Castillo-Rodriguez RA, Trejo-Solis C, Cabrera-Cano A, Gomez-Manzo S, Davila-Borja VM (2022) Hypoxia as a modulator of inflammation and immune response in cancer. Cancers (Basel) 14(9):2291

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chandra T, Kirschner K, Thuret JY, Pope BD, Ryba T, Newman S, Ahmed K, Samarajiwa SA, Salama R, Carroll T et al (2012) Independence of repressive histone marks and chromatin compaction during senescent heterochromatic layer formation. Mol Cell 47:203–214

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen K, Chen Z, Wu D, Zhang L, Lin X, Su J, Rodriguez B, Xi Y, Xia Z, Chen X et al (2015) Broad H3K4me3 is associated with increased transcription elongation and enhancer activity at tumor-suppressor genes. Nat Genet 47:1149–1157

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen X, Ma Q, Shang Z, Niu Y (2020) Super-enhancer in prostate cancer: transcriptional disorders and therapeutic targets. NPJ Precis Oncol 4:31

Article  PubMed  PubMed Central  Google Scholar 

Chen PB, Fiaux PC, Zhang K, Li B, Kubo N, Jiang S, Hu R, Rooholfada E, Wu S, Wang M et al (2022) Systematic discovery and functional dissection of enhancers needed for cancer cell fitness and proliferation. Cell Rep 41:111630

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chen Y, Liang R, Li Y, Jiang L, Ma D, Luo Q, Song G (2024) Chromatin accessibility: biological functions, molecular mechanisms and therapeutic application. Signal Transduct Target Ther 9:340

Article  PubMed  PubMed Central  Google Scholar 

Cheng Y, Pei G, Zhang H, Hou Y, Sun L, Xu H, Lv Y, Wu X (2025) Super enhancers as key drivers of gene regulatory networks in normal and malignant hematopoiesis. Front Cell Dev Biol 13:1674470

Article  PubMed  PubMed Central  Google Scholar 

Chipumuro E, Marco E, Christensen CL, Kwiatkowski N, Zhang T, Hatheway CM, Abraham BJ, Sharma B, Yeung C, Altabef A et al (2014) CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer. Cell 159:1126–1139

Article  CAS  PubMed  PubMed Central  Google Scholar 

Choi H, Pavelka N (2011) When one and one gives more than two: challenges and opportunities of integrative omics. Front Genet 2:105

PubMed  Google Scholar 

Chung C, Sweha SR, Pratt D, Tamrazi B, Panwalkar P, Banda A, Bayliss J, Hawes D, Yang F, Lee HJ et al (2020) Integrated metabolic and epigenomic reprograming by H3K27M mutations in diffuse intrinsic pontine gliomas. Cancer Cell 38:334–349 e339

Article  CAS  PubMed  PubMed Central  Google Scholar 

Davies A, Zoubeidi A, Beltran H, Selth LA (2023) The transcriptional and epigenetic landscape of cancer cell lineage plasticity. Cancer Discov 13:1771–1788

Article  CAS  PubMed  PubMed Central  Google Scholar 

Dhar SS, Brown C, Rizvi A, Reed L, Kotla S, Zod C, Abraham J, Abe JI, Rajaram V, Chen K et al (2025) Heterozygous Kmt2d loss diminishes enhancers to render medulloblastoma cells vulnerable to combinatory inhibition of LSD1 and OXPHOS. Cell Rep 44:115619

Article  CAS  PubMed  PubMed Central  Google Scholar 

Emran AA, Marzese DM, Menon DR, Stark MS, Torrano J, Hammerlindl H, Zhang G, Brafford P, Salomon MP, Nelson N et al (2018) Distinct histone modifications denote early stress-induced drug tolerance in cancer. Oncotarget 9:8206–8222

Article  PubMed  Google Scholar 

Esteller M, Dawson MA, Kadoch C, Rassool FV, Jones PA, Baylin SB (2024) The epigenetic hallmarks of cancer. Cancer Discov 14:1783–1809

Article  CAS  PubMed  Google Scholar 

Ezponda T, Licht JD (2014) Molecular pathways: deregulation of histone h3 lysine 27 methylation in cancer-different paths, same destination. Clin Cancer Res 20:5001–5008

Article  CAS